Immunotherapy in Melanoma | Specialty

The OncLive Immunotherapy in Melanoma condition center page is a comprehensive resource for clinical news and expert insights on available and investigational immunotherapies in melanoma and other skin cancers. This page features news articles, interviews in written and video format, and podcasts that focus on updates with checkpoint inhibitors and the ongoing research with this type of treatment.

Adjuvant Dabrafenib/Trametinib Doubles RFS for BRAF+ Melanoma

September 11th 2017

Adjuvant treatment with dabrafenib and trametinib reduced the risk of relapse or death by 53% compared with placebo for patients with stage III BRAF-mutant melanoma.

PD-1/IDO Combination Active in Advanced Melanoma

September 10th 2017

A majority of patients with advanced melanoma responded to the combination of pembrolizumab and the investigational IDO1 inhibitor epacadostat.

Binimetinib Adds to Encorafenib PFS Benefit for BRAF+ Melanoma

September 9th 2017

The combination of encorafenib and binimetinib demonstrated significant improvements in PFS compared with single-agent vemurafenib or encorafenib for patients with BRAF-mutant advanced melanoma.

FDA Grants Cemiplimab Breakthrough Designation for CSCC

September 9th 2017

The FDA has granted a breakthrough therapy designation to cemiplimab (REGN2810) for the treatment of adults with metastatic cutaneous squamous cell carcinoma (CSCC) and adults with locally advanced and unresectable CSCC.

Dr. Gandara Discusses PD-L1 as a Biomarker in Lung Cancer

September 8th 2017

David R. Gandara, MD, director, Thoracic Oncology Program, professor, senior advisor to director, UC Davis Comprehensive Cancer Center, treasurer, International Association for the Study of Lung Cancer, discusses PD-L1 as a biomarker in lung cancer.

Dr. Ross Discusses the Future Treatment Landscape of Melanoma

September 8th 2017

Merrick I. Ross, MD, professor, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses the future treatment landscape of melanoma.

Update Confirms Benefit of Pembrolizumab Plus Indoximod in Melanoma

September 7th 2017

Adding the IDO inhibitor indoximod to pembrolizumab (Keytruda) led to an overall response rate of 61% in patients with advanced melanoma.

FDA Grants LN-144 Fast Track Status for Melanoma

September 1st 2017

The FDA has granted LN-144, an adoptive cell therapy that uses tumor-infiltrating lymphocyte technology developed by Iovance Biotherapeutics, a fast track designation for the treatment of patients with advanced melanoma.

Dr. Daud Discusses the Current Status of Immunotherapy in Melanoma

August 28th 2017

Adil Daud, MD, clinical professor, Department of Medicine, Helen Diller Family Comprehensive Cancer Center, at University of California, San Francisco, discusses the current status of immunotherapy in melanoma.

Dr. Grob on the Tolerability and Efficacy of Ipilimumab in Melanoma

August 24th 2017

Jean Jacques Grob, MD, PhD, professor of dermatology at the Hospital de la Timone, discusses the tolerability and efficacy of ipilimumab (Yervoy) for melanoma.

Andtbacka Discusses Long-Term Data and Next Steps With T-VEC in Melanoma

August 22nd 2017

Robert Andtbacka, MD, discusses the long-term results for T-VEC in melanoma and the remaining challenges with the oncolytic immunotherapy.

Dr. Wilson on Choosing Between BRAF/MEK Therapies for Patients With Melanoma

August 16th 2017

Melissa A. Wilson, MD, PhD, an assistant professor of medicine at Perlmutter Cancer Center at NYU Langone Medical Center, discusses how physicians select between the 2 BRAF/MEK inhibitor combination regimens for their patients with melanoma.

RT Options Evolving in Oligometastatic Lung Cancer Landscape and Beyond

August 14th 2017

Billy W. Loo Jr, MD, PhD, discusses the advancements in radiation therapy options for patients with lung cancer, how SABR has improved outcomes for patients, and the intriguing combinations being explored with RT and immunotherapy.

Expert Discusses Long-Term Dabrafenib/Trametinib Data in Melanoma

August 10th 2017

Georgina V. Long, BSc, PhD, MBBS, discusses recent data with the combination of dabrafenib (Tafinlar) plus trametinib (Mekinist) in patients with BRAF V600-mutant unresectable or metastatic melanoma.

Dr. Stein on Targeted Therapies for Melanoma

August 4th 2017

Jennifer A. Stein, MD, PhD, an associate professor of dermatology at NYU Langone Medical Center, discusses targeted therapies for patients with melanoma.

Dr. Meehan on Importance of IHC Testing in Melanoma

July 31st 2017

Shane A. Meehan, MD, associate professor, Ronald O. Perelman Department of Dermatology, associate professor, Department of Pathology, director of the Dermatopathology Fellowship Training Program, and director of the Dermatopathology Section at New York University Langone Medical Center, discusses the importance of immunohistochemistry (IHC) testing in melanoma.

Dr. Berman on Evolving Role of Surgery in Melanoma

July 31st 2017

Russell Berman, MD, division chief of Surgical Oncology at NYU Langone Medical Center, NYU Langone School of Medicine, shares insight on the evolving role of surgery in patients with melanoma.

Dr. Stein Discusses Skin-Related AEs With Melanoma Treatment

July 28th 2017

Jennifer A. Stein, MD, PhD, an associate professor of dermatology at New York University School of Medicine in New York, discusses the skin-related adverse events (AEs) associated with melanoma treatment.

Dr. Shapiro on Surgical Advancements in Field of Melanoma

July 28th 2017

Richard L. Shapiro, MD, associate professor, Department of Surgery, New York University Langone Medical Center, discusses recent advancements related to surgery in the field of melanoma.

Dr. Pavlick on Adjuvant Immunotherapy in High-risk Melanoma

July 27th 2017

Anna C. Pavlick, DO, associate professor of hematology and medical oncology and medical director of the Clinical Trials Office at the Perlmutter Cancer Center at NYU Langone Medical Center, discusses the need for adjuvant immunotherapy in patients with high-risk melanoma.